HTG MOLECULAR DIAGNOSTICS, INC

Profile

Company Names

HTG MOLECULAR DIAGNOSTICS, INC
HTG MOLECULAR DIAGNOSTICS INC
HIGH THROUGHPUT GENOMICS INC

Addresses

3430 E. GLOBAL LOOP, TUCSON, AZ 85706

Phone Numbers

877-289-2615

 

Entity Type:

CORPORATION

Industry:

OTHER HEALTH CARE, BIOTECHNOLOGY

Year Incorporated:

> 5 years ago

State Incorporated:

DELAWARE

Total Amount Raised:

$46,444,354.00

Number of Funding Rounds:

9
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
9
2022-03-21 
$7,499,999.00 
$20,884,736.00 
$13,384,737.00 
Equity 
8
2019-09-24 
$3,463,480.00 
$3,517,597.00 
$54,117.00 
 
7
2015-01-14 
$0.00 
$18,023,596.00 
$18,023,596.00 
Debt 
6
2014-08-22 
$0.00 
$800,000.00 
$800,000.00 
 
5
2014-02-04 
$7,476,879.00 
$21,736,348.00 
$14,259,469.00 
Equity 
4
2012-11-02 
$7,555,498.00 
$27,000,000.00 
$19,444,502.00 
Equity 
3
2011-02-18 
$14,399,998.00 
$14,399,998.00 
$0.00 
Equity 
2
2010-07-30 
$1,738,500.00 
$1,738,500.00 
$0.00 
Debt 
1
2008-11-03 
$4,310,000.00 
$4,310,000.00 
$0.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
PETER 
 
BISGAARD 
DIRECTOR
M2 GROUP HOLDINGS INC   |  LIGHT SCIENCES ONCOLOGY INC   |  OTONOMY, INC.   |  HIGH THROUGHPUT GENOMICS INC   |  HTG MOLECULAR DIAGNOSTICS INC   |  ALTHEOS, INC.   |  THESAN PHARMACEUTICALS, INC.   |  CETERIX ORTHOPAEDICS, INC.   |  HTG MOLECULAR DIAGNOSTICS, INC   |  RA PHARMACEUTICALS, INC.   |  OUTPOST MEDICINE, LLC   |  BOLT BIOTHERAPEUTICS, INC.   |  EARGO, INC.   |  ONCXERNA THERAPEUTICS, LTD.   |  MAPLIGHT THERAPEUTICS, INC.   |  ADDITION THERAPEUTICS, INC.
KIRK 
A. 
COLLAMER 
EXECUTIVE OFFICER
HIGH THROUGHPUT GENOMICS INC   |  HTG MOLECULAR DIAGNOSTICS INC
HARRY 
 
GEORGE 
DIRECTOR
MEDIPACS, INC   |  HIGH THROUGHPUT GENOMICS INC   |  LUMIDIGM INC   |  SYNCARDIA SYSTEMS INC   |  HTG MOLECULAR DIAGNOSTICS INC   |  ADICYTE, INC.   |  REHNU, INC.   |  HTG MOLECULAR DIAGNOSTICS, INC   |  POST.BID.SHIP., INC.   |  RXACTUATOR, INC.
HARRY 
A. 
GEORGE 
DIRECTOR
AMPLIMED CORP   |  CALIMMUNE, INC.   |  HTG MOLECULAR DIAGNOSTICS, INC
SIMEON 
 
GEORGE 
DIRECTOR
SEMPRUS BIOSCIENCES CORP   |  GENOCEA BIOSCIENCES, INC.   |  HTG MOLECULAR DIAGNOSTICS INC   |  AUXOGYN INC   |  EFFECTOR THERAPEUTICS, INC.   |  HTG MOLECULAR DIAGNOSTICS, INC   |  AUXOGYN, INC.   |  PRINCIPIA BIOPHARMA INC.   |  PROGYNY, INC.   |  TP THERAPEUTICS, INC.   |  CRISPR THERAPEUTICS AG   |  SR ONE CO-INVEST I, LLC   |  SIMCHA THERAPEUTICS HOLDING COMPANY, LLC   |  ADARX PHARMACEUTICALS, INC.   |  SR ONE CAPITAL FUND II-B, LP   |  SR ONE CAPITAL FUND II-A, LP   |  AVENZO THERAPEUTICS, INC.   |  REZO THERAPEUTICS, INC.   |  SR ONE CAPITAL FUND III, LP
MICHELLE 
R. 
GRIFFIN 
DIRECTOR
HTG MOLECULAR DIAGNOSTICS, INC
DONALD 
W. 
GRIMM 
DIRECTOR
HIGH THROUGHPUT GENOMICS INC   |  LIFE TECHNOLOGIES CORP   |  HTG MOLECULAR DIAGNOSTICS INC
ANN 
F. 
HANHAM 
DIRECTOR
ENDOCYTE INC   |  SCYNEXIS INC   |  HTG MOLECULAR DIAGNOSTICS, INC
DON 
M. 
HARDISON 
DIRECTOR
HTG MOLECULAR DIAGNOSTICS, INC
JOHN 
M. 
HOLLIMAN 
DIRECTOR
AMPLIMED CORP   |  HIGH THROUGHPUT GENOMICS INC
MOLLY 
 
HOULT 
DIRECTOR
HIGH THROUGHPUT GENOMICS INC   |  HTG MOLECULAR DIAGNOSTICS INC   |  HTG MOLECULAR DIAGNOSTICS, INC
TIMOTHY 
 
JOHNSON 
EXECUTIVE OFFICER, DIRECTOR
HIGH THROUGHPUT GENOMICS INC   |  PATHOLOGY HOLDINGS, INC.   |  HTG MOLECULAR DIAGNOSTICS INC   |  CD OPCO HOLDING CORP   |  HTG MOLECULAR DIAGNOSTICS, INC   |  BLACKSTONE REAL ESTATE SPECIAL SITUATIONS FUND L.P.   |  BLACKSTONE REAL ESTATE DEBT STRATEGIES III L.P.   |  GROUP TEN METALS INC   |  LOGICSOURCE, INC.   |  LSI HOLDING COMPANY, LLC   |  LUXWALL, INC.   |  BLACKSTONE REAL ESTATE DEBT STRATEGIES V (LUX) SCSP   |  BLACKSTONE REAL ESTATE DEBT STRATEGIES V (FEEDER FUND) (LUX) SCSP   |  BLACKSTONE REAL ESTATE DEBT STRATEGIES V L.P.   |  BLACKSTONE REAL ESTATE DEBT STRATEGIES V (FEEDER FUND) L.P.
TIMOTHY 
B. 
JOHNSON 
DIRECTOR
KALYPTO MEDICAL INC   |  BARD MICRO-CAP VALUE FUND, L.P.   |  HTG MOLECULAR DIAGNOSTICS, INC
CHRISTOPHER 
 
KIRITSY 
DIRECTOR
AVAXIA BIOLOGICS, INC   |  ARISAPH PHARMACEUTICALS INC   |  PIERIS PHARMACEUTICALS, INC.   |  HTG MOLECULAR DIAGNOSTICS, INC
JAMES 
T. 
LAFRANCE 
DIRECTOR
HTG MOLECULAR DIAGNOSTICS, INC   |  ASPIRA WOMEN-S HEALTH INC.
JOHN 
 
LUBNIEWSKI 
EXECUTIVE OFFICER, DIRECTOR
HTG MOLECULAR DIAGNOSTICS, INC
LEE 
R. 
MCCRACKEN 
DIRECTOR
HTG MOLECULAR DIAGNOSTICS, INC
SHAUN 
 
MCMEANS 
EXECUTIVE OFFICER
HTG MOLECULAR DIAGNOSTICS INC   |  HTG MOLECULAR DIAGNOSTICS, INC
BRUCE 
E. 
SELIGMANN 
DIRECTOR
HIGH THROUGHPUT GENOMICS INC
LARRY 
 
SENOUR 
DIRECTOR
HIGH THROUGHPUT GENOMICS INC   |  HTG MOLECULAR DIAGNOSTICS INC   |  HTG MOLECULAR DIAGNOSTICS, INC
LEWIS 
 
SHUSTER 
DIRECTOR
RESPONSE BIOMEDICAL CORP   |  MAST THERAPEUTICS, INC.   |  HTG MOLECULAR DIAGNOSTICS, INC   |  CLEAVE BIOSCIENCES, INC.
JIM 
 
WEERSING 
DIRECTOR
HIGH THROUGHPUT GENOMICS INC   |  HTG MOLECULAR DIAGNOSTICS INC   |  HTG MOLECULAR DIAGNOSTICS, INC
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2022-03-25
D
Link
OTHER HEALTH CARE 
LABORATORY ANALYTICAL INSTRUMENTS [3826] 
DECLINE TO DISCLOSE 
Equity 
2022-03-21 
2019-10-01
D
Link
OTHER HEALTH CARE 
LABORATORY ANALYTICAL INSTRUMENTS [3826] 
DECLINE TO DISCLOSE 
 
2019-09-24 
2015-01-23
D
Link
BIOTECHNOLOGY 
LABORATORY ANALYTICAL INSTRUMENTS [3826] 
DECLINE TO DISCLOSE 
Debt 
2015-01-14 
2014-09-03
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
 
2014-08-22 
2014-02-13
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2014-02-04 
2012-11-14
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2012-11-02 
2011-06-17
D/A
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2011-02-18 
2011-03-01
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2011-02-18 
2010-08-06
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2010-07-30 
2009-07-23
D/A
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2008-11-03 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
CANTOR FITZGERALD + CO.
134